From January 1, 2022, the new version of the national medical insurance drug list was officially implemented. The newly added 74 out-of-list drugs involve 21 clinical groups, including 20 drugs for chronic diseases such as hypertension, diabetes, hyperlipidemia and psychosis, 18 kinds of tumor drugs, 15 kinds of anti-infection drugs such as hepatitis C and AIDS, 7 kinds of drugs for rare diseases, 2 kinds of drugs for the treatment of new crown pneumonia, and 12 kinds of drugs in other fields, and patients benefit from a wide range.
It is understood that the new version of the national medical insurance catalogue has a total of 74 kinds of drugs newly listed, including abexili tablets, ussnuzumab, aminopyridine extended-release tablets, etc., accurately complementing the disease areas with urgent drug needs such as tumors, immunity, anti-infection, and rare diseases, effectively improving the affordability of innovative drugs, and benefiting a wider range of patients. Among them, the reporter learned that after the innovative biological agent usonuzumab for the treatment of Crohn's disease entered the medical insurance, the first prescription in the country was issued in the First Affiliated Hospital of Sun Yat-sen University, and the annual treatment cost dropped by 87%, which also marked that patients with Crohn's disease could have more treatment options while the treatment cost was greatly reduced.
According to reports, Crohn's disease (CD for short) is a chronic inflammatory disease involving the gastrointestinal tract, which cannot be cured at present, and most patients need lifelong medication. In recent years, the prevalence of CD in China has gradually increased, and the disease is more common among young and middle-aged people, which brings a heavy burden to patients and families, and seriously affects the lives and work of patients.
Image source: Visual China (pictures and text are irrelevant)
On January 1, 2022, CD patient Li Ping (pseudonym) had important significance. Since the diagnosis of CD in 2020, Li Ping began to use the biological agent usonomumab. However, due to the fact that the drug had not yet been included in medical insurance at that time, the treatment in the past two years had brought a lot of burden to Li Ping's family. After learning that uscimolumab can be reimbursed by medical insurance, Li Ping was very excited: "I am very grateful to the country's medical insurance policy, which is really a huge good news for patients with Crohn's disease who need long-term medication!" ”
Crohn's disease is not uncommon
Standardizing treatment is key
Crohn's disease is a type of Inflammatory Bowel Disease (IBD). In recent years, the incidence of IBD in China has gradually increased, and it is expected that the number of patients will reach 1.5 million in 2025. The current treatment goal of IBD is to alleviate clinical symptoms, heal the mucous membrane of the lesion, prevent complications, and improve the quality of life of patients.
As a leader in the field of IBD treatment in China, Professor Chen Minhu, vice president of the First Affiliated Hospital of Sun Yat-sen University and chairman of the Gastroenterology Branch of the Chinese Medical Association, said that under the guidance of specialist doctors, through standardized treatment, most patients' conditions can be effectively controlled, and they can even live like normal people: "But in the treatment process, patients must cooperate closely with doctors, follow medical advice, adhere to long-term treatment, and achieve better prognosis." ”
Professor Chen Minhu said that some patients stop the drug without authorization and do not follow up because their symptoms improve or are worried about the adverse reactions of the drug, which is often easy to cause the recurrence or aggravation of the disease. It is understood that the standardized use of therapeutic drugs, including biological agents, under the guidance of specialists, can achieve safe and effective treatment and long-term remission of the disease. "On the other hand, as innovative drugs enter the medical insurance list, the burden on patients is reduced, and medication compliance can also be well improved." Professor Chen Minhu said.
The therapeutic burden is also gradually no longer
The main contradiction that hinders the treatment of patients
This year's new version of the medical insurance catalogue new drugs involving 21 clinical groups, covering a number of major disease areas, in addition to allowing patients to go one step further in the "medical burden reduction", it is expected that in 2022, the cumulative burden reduction for patients will exceed 30 billion yuan.
Most of the IBD-prone groups are young adults, and the onset of the disease is at the time of the rising period of the patient's life. Innovative biologics are included in medicament, alleviating the worries of this group and enabling them to achieve their goals in life and career development like normal people.
Professor Chen Minhu pointed out that with the improvement of disease cognition and diagnosis and treatment methods, more patients will be found in the early stage of the disease and will be well treated.
"Compared with the limited treatment methods many years ago, at present, IBD patients can get a more suitable treatment plan after diagnosis, and under the blessing of medical insurance reimbursement policy, the treatment burden is gradually no longer the main contradiction hindering patient treatment." Professor Chen Minhu said, "In the future, more IBD patients will be able to achieve the treatment goal of long-term remission of the disease after treatment, and live like normal people. ”
Source | Yangcheng Evening News, Golden Sheep Network, Yangcheng Pie
Text | Yangcheng Evening News all-media reporter Zhang Hua
Edit | Shushu
Proofreading | Li Hongyu
Review and sign | Zhou Lerui
![Inflammatory bowel disease: Western and meat-based dietary patterns are more likely to develop IBD[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)